Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumours [3]

Acta Oncologica

Volumn 47, Issue 1, 2008, Pages 153-155

  Van Der Horst Schrivers, Anouk N A ^a   Slot, Madeleine H E Bruins ^a   Willemse, Pax H B ^a   Kema, Ido P ^a   De Vries, Elisabeth G E ^a   Wymenga, A N Machteld ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; INTERFERON; SOMATOSTATIN DERIVATIVE; SUNITINIB; VASCULOTROPIN;

ANGIOGENESIS; ARTHRITIS; CANCER THERAPY; DIARRHEA; DRUG POTENTIATION; FATIGUE; HEART FAILURE; HUMAN; LETTER; METASTASIS; NEUROENDOCRINE TUMOR; POLYNEUROPATHY; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; FLUOROURACIL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; NEUROENDOCRINE TUMORS; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37549025863     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701449403     Document Type: Letter

References (7)

1. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: Regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004;80(Suppl 1):85-93.
2. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109:1478-86.
3. Andreyev HJ, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995;13:1486-92.
4. Nilsson A, Janson ET, Eriksson B, Larsson A. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. Anticancer Res 2001;21:4087-90.
5. Yao JC, Ng C, Hoff PM, Phan AT, Hess K, Chen H, et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 2005;23:16S Abstract 4007.
6. Kulke HM, Lenz HJ, Meropol NJ, Posey J, Ryan P, Picus J, et al. A phase 2 study to evaluate the efficacy of SU11248 in patients with unresectable neuroendocrine tumors. J Clin Oncol 2005;23:16S Abstract 4008.
7. Bello CL, Deprimo SE, Friece C, Smeraglia J, Sherman L, Tye L, et al. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. J Clin Oncol 2006;24:18S Abstract 4045.